病例报告：度普利尤单抗会增加特应性皮炎患者头颈部感染的几率。
Case report: Dupilumab leads to an increased chance of head and neck infection in atopic dermatitis patients.
作者信息
Chen Min, Gao Kai, Ali Kamran, Shan Jinpeng, Qiu YunMi, Xie Tianci, Yu Yiling, Wu Liming
机构信息
Department of Dermatology, The Fourth School of Medicine Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Department of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
出版信息
Front Med (Lausanne). 2023 Mar 8;10:1027589. doi: 10.3389/fmed.2023.1027589. eCollection 2023.
Dupilumab was the first biological medication licensed to treat atopic dermatitis (AD), and it has shown remarkable effectiveness and safety in the treatment of moderate-to-severe atopic dermatitis. There are limited drug-related adverse events associated with dupilumab in atopic dermatitis (AD) treatment. Here, we present two cases of local infection during the treatment of atopic dermatitis with dupilumab.
度普利尤单抗是首个获批用于治疗特应性皮炎（AD）的生物制剂，并且在治疗中重度特应性皮炎方面显示出显著的有效性和安全性。在特应性皮炎（AD）治疗中，与度普利尤单抗相关的药物不良事件有限。在此，我们报告两例在使用度普利尤单抗治疗特应性皮炎期间发生局部感染的病例。
Zotero 插件